Odyssey Therapeutics
ODTX
17.24
-0.84
-4.65%
Odyssey Therapeutics
US · ODTX
#3348 by market cap
Listed 2026
17.24
-0.84
-4.65%
Live - 5344 symbols - heartbeat 225s ago
· 2026-10-08 09:58
After-hours
18.08
0.00%
- Market cap
- 828.53M
- P/E (TTM)i
- -5.16
- P/Bi
- 1.97
- EPSi
- -3.15
- Div yieldi
- 0.00%
- 52W posi
- 15%
Reader sentiment
Are you bullish or bearish on ODTX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is -3.52, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 4 years
Latest year -33.45% YoY
Margins
- Operating margin
- -5,415.19%
- Net margin
- -4,994.86%
Key ratios & quality
- Altman Z-Scorei
- -3.52
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | 0 | 1.04M | 4.47M | 2.98M |
| Gross profit | -- | -- | -- | -- |
| Selling & admin expenses | 21.02M | 22.20M | 27.12M | 37.52M |
| Research & development | 101.76M | 112.28M | 112.58M | 126.62M |
| Operating profit | -122.78M | -133.44M | -135.22M | -161.16M |
| Pretax profit | -124.32M | -125.49M | -128.85M | -149.57M |
| Tax | 347.00K | 447.00K | 469.00K | -927.00K |
| Net profit | -124.67M | -125.94M | -129.32M | -148.65M |
| Basic EPS | -5 | -1 | -5 | -5 |
| Diluted EPS | -4.52 | -1.32 | -4.73 | -5.39 |
| Line item | 2024-09 | 2024-12 | 2025-03 | 2025-06 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | -- | 1.76M | 1.92M | 959.00K | 0 | 0 |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | -- | 7.40M | 7.95M | 13.22M | 7.35M | 10.51M |
| Research & development | -- | 31.48M | 38.77M | 30.23M | 32.32M | 36.23M |
| Operating profit | -- | -37.12M | -44.81M | -42.49M | -39.67M | -46.74M |
| Pretax profit | -- | -35.89M | -38.30M | -41.21M | -38.20M | -52.80M |
| Tax | -- | 47.00K | 140.00K | 30.00K | 63.00K | -8.00K |
| Net profit | -- | -35.93M | -38.44M | -41.24M | -38.26M | -52.79M |
| Basic EPS | -- | -1 | -1 | -1 | -1 | -2 |
| Diluted EPS | -- | -1.34 | -1.39 | -1.50 | -0.81 | -1.74 |
Balance sheet
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total current assets | 248.71M | 192.54M | 135.51M | 190.66M |
| Cash & ST investments | 241.04M | 187.00M | 129.35M | 181.36M |
| Inventory | -- | -- | -- | -- |
| Total assets | 317.15M | 286.52M | 197.44M | 269.79M |
| Total current liabilities | 22.80M | 22.09M | 28.42M | 26.48M |
| Short-term debt | 3.35M | 3.86M | 4.58M | 5.21M |
| Long-term debt | 4.76M | -- | -- | -- |
| Total liabilities | 461,770,000.00 | 549,229,000.00 | 579,962,000.00 | 758,066,000.00 |
| Total equity | -144.62M | -262.71M | -382.53M | -488.28M |
| Retained earnings | -158.17M | -289.09M | -419.49M | -568.14M |
| Line item | 2024-09 | 2024-12 | 2025-03 | 2025-06 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 159.83M | 135.51M | -- | -- | 185.10M | 321.46M |
| Cash & ST investments | 154.90M | 129.35M | -- | -- | 175.75M | 310.58M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 221.54M | 197.44M | -- | -- | 229.07M | 483.85M |
| Total current liabilities | 25.11M | 28.42M | -- | -- | 22.21M | 28.30M |
| Short-term debt | 4.45M | 4.58M | -- | -- | 5.37M | 5.47M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 570,801,000.00 | 579,962,000.00 | -- | -- | 752,764,000.00 | 62,629,000.00 |
| Total equity | -349.27M | -382.53M | -- | -- | -523.69M | 421.22M |
| Retained earnings | -382.66M | -419.49M | -- | -- | -606.40M | -659.19M |
Cash flow
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Operating cash flow | -99.84M | -112.73M | -117.47M | -129.47M |
| Depreciation & amortization | 2.76M | 4.91M | 5.19M | 4.91M |
| Free cash flow | -112.87M | -117.78M | -118.24M | -130.70M |
| Dividends paid | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- |
| Ending cash balance | 241.67M | 56.00M | 62.35M | 44.90M |
| Line item | 2024-09 | 2024-12 | 2025-03 | 2025-06 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -- | -34.29M | -38.62M | -34.26M | -41.04M | -34.51M |
| Depreciation & amortization | -- | 1.29M | 1.30M | 1.27M | 1.17M | 1.04M |
| Free cash flow | -- | -34.55M | -39.55M | -34.29M | -41.18M | -34.69M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | -- | 62.35M | 58.12M | 166.21M | 39.17M | 85.48M |
Returns & efficiency
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| ROE %i | -- | -- | -- | -- |
| ROA %i | -39.31 | -43.37 | -53.89 | -63.63 |
| ROIC %i | -- | -- | -- | -- |
| 5-year avg ROE %i | -- | -- | -- | -- |
| EBIT margin %i | -- | -12,069.05 | -2,880.90 | -5,025.44 |
| FCF / sales %i | -- | -- | -- | -- |
| Current ratioi | 10.91 | 8.72 | 4.77 | 7.20 |
| Quick ratioi | 10.57 | 8.47 | 4.55 | 6.85 |
| Debt / assetsi | 13.40 | 12.00 | 15.70 | 10.05 |
| LT debt / equityi | -- | -- | -- | -- |
| Interest coveragei | -426.21 | -373.60 | -7,157.44 | -8,797.47 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- |
| Line item | 2024-09 | 2024-12 | 2025-03 | 2025-06 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -- | -- | -- | -37.99 |
| ROA %i | -57.51 | -53.89 | -- | -- | -64.82 | -33.07 |
| ROIC %i | -- | -- | -- | -- | -- | -37.84 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -4,051.53 | -2,880.90 | -- | -- | -14,125.99 | -162,652.53 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 6.37 | 4.77 | -- | -- | 8.33 | 11.36 |
| Quick ratioi | 6.17 | 4.55 | -- | -- | 7.91 | 10.98 |
| Debt / assetsi | 14.49 | 15.70 | -- | -- | 11.41 | 5.13 |
| LT debt / equityi | -- | -- | -- | -- | -- | 4.60 |
| Interest coveragei | -5,795.62 | -7,157.44 | -- | -- | -5,978.12 | -3,744.79 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Standard of care for patients suffering from autoimmune and inflammatory diseases100.00%
Region
United States100.00%
Quote time 2026-10-08 09:58:49 · For reference only, not investment advice and not tailored to your situation.